Results 1 to 10 of about 25,219 (211)

Impact of ileostomy creation on apixaban plasma concentrations: a retrospective case-series [PDF]

Annals of Saudi Medicine
BACKGROUND: Apixaban is a direct-acting oral anticoagulant indicated for stroke and systemic embolism prevention in atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE).
Hakeam A. Hakeam, Sandra McGrath, Ghader Alrebeh, Abdullah F. Alrebdi   +3 more
doaj   +2 more sources

Thrombin generation in HeartMate 3 patients on apixaban and vitamin K antagonists: Variability limits clinical applicability [PDF]

JHLT Open
Apixaban is increasingly replacing vitamin K antagonists (VKAs) during HeartMate 3 (HM3) left ventricular assist device support, but its pharmacodynamics in this setting remain poorly understood.
Charlotte J. Van Edom, MD, Walter Droogné, MD, Steven Jacobs, MD, PhD, Marc Jacquemin, MD PhD, Christine Van Laer, PhD, Joeri Van Puyvelde, MD, PhD, Dirk Vlasselaers, MD, PhD, Katrien Vandersmissen, Thomas Vanassche, MD, PhD, Bart Meyns, MD, PhD   +9 more
doaj   +2 more sources

Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome [PDF]

Kidney Medicine
Rationale & Objective: Venous thromboembolism is a serious complication of nephrotic syndrome (NS). Guidelines recommend prophylactic anticoagulation with warfarin or low molecular weight heparin.
Sarah Kelddal, Erik L. Grove, Camilla L. Duus, Louis B. Nygaard, Tilde Kristensen, Frank H. Mose, Jon W. Gregersen, Anne-Mette Hvas, Henrik Birn   +8 more
doaj   +2 more sources

Real‐World Impact of Amiodarone on Apixaban Population Pharmacokinetics in Hospitalized Patients [PDF]

Clinical and Translational Science
Despite common coadministration in nonvalvular atrial fibrillation (NVAF), there is minimal evidence regarding the impact of concomitant amiodarone use on apixaban pharmacokinetics (PK).
Samantha Kolowrat, Chazmyn Riley, Kevin Lam, Lynda Thomson, Douglas F. Stickle, Walter K. Kraft   +5 more
doaj   +2 more sources

Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs

Frontiers in Veterinary Science, 2021
Thrombosis is common in critically ill dogs and causes considerable morbidity and mortality. The direct factor Xa inhibitor apixaban is safe, efficacious, and convenient in humans.
Noelle D. Herrera, Ingvild Birschmann, Monika Wolny, Mark G. Papich, Marjory B. Brooks, Robert Goggs   +5 more
doaj   +1 more source

Apixaban [PDF]

Hospital Pharmacy, 2013
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J, Levien, Terri L, Baker, Danial E   +2 more
openaire   +3 more sources

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. [PDF]

PLoS ONE, 2018
Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin.
Xiaoyan Li, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Gregory Y H Lip, Steve Deitelzweig   +11 more
doaj   +1 more source

Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation

Scientific Reports, 2021
In some clinical situations, measurements of anticoagulant effect of apixaban may be needed. We investigated the inter- and intra-individual apixaban variability in patients with atrial fibrillation and correlated these results with clinical outcome.
Alenka Mavri, Nina Vene, Mojca Božič-Mijovski, Marko Miklič, Lisbeth Söderblom, Anton Pohanka, Rickard E. Malmström, Jovan Antovic   +7 more
doaj   +1 more source

Apixaban [PDF]

Reactions Weekly, 2021
  +7 more sources

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. [PDF]

PLoS ONE, 2012
BACKGROUND: Apixaban was shown to be superior to adjusted-dose warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke, and associated with reduced rates of ...
Soyon Lee, Rachel Mullin, Jon Blazawski, Craig I Coleman   +3 more
doaj   +1 more source